i sac o n s u l t a n tf o rA s t r a Z e n e c a .E .H .i sa ne m p l o y e eo fa n ds t o c k h o l d e r in AstraZeneca. J. R. has received re search support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, Intarcia, Janssen, Lexicon, Merck, Novo Nor-disk, Pfizer and Sanofi, and has served on advisory boards of or receivedconsulting honoraria from AstraZene ca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Intarcia, Janssen, Novo Nordisk and Sanofi. Author contributions C. G. contributed to study design and conduct, approved the report,participated in the acquisition and interpretation of data, and pro-vided critical revisions to the manuscript. J. P. F., A. S., S. J. and J. R.participated in the acquisition and interpretation of data and providedcritical revisions to the manuscript. H. W. participated in the analysis and interpretation of data and provided critical revisions to the manu-